YWHAQ and cytomegalovirus infection: Finally, we asked if the inability of UL97-S13A to bind 14-3-3 proteins impacts the ability of UL97 to render infected cells sensitive to the antiviral prodrug ganciclovir (GCV) that it phosphorylates and activates (47, 48) or impacts the sensitivity of UL97 itself to maribavir (MBV), a small molecule inhibitor of UL97 kinase activity (49) recently approved by the FDA for patients with post-transplant CMV infections that do not respond to available antivirals (50, 51).